Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19), with a clinical outcome ranging from mild to severe, including death. To date, it is unclear why some patients develop severe symptoms. Many authors have suggested the involvement of vitamin D in reducing the risk of infections; thus, we retrospectively investigated the 25-hydroxyvitamin D (25(OH)D) concentrations in plasma obtained from a cohort of patients from Switzerland. In this cohort, significantly lower 25(OH)D levels (p = 0.004) were found in PCR-positive for SARS-CoV-2 (median value 11.1 ng/mL) patients compared with negative patients (24.6 ng/mL); this was also confirmed by stratifying patients according to age >70 years. On the basis of this preliminary observation, vitamin D supplementation might be a useful measure to reduce the risk of infection. Randomized controlled trials and large population studies should be conducted to evaluate these recommendations and to confirm our preliminary observation.

25-hydroxyvitamin D concentrations are lower in patients with positive PCR for SARS-CoV-2

D'avolio A.
First
;
Avataneo V.;Manca A.;Cusato J.;De Nicolo A.;
2020

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19), with a clinical outcome ranging from mild to severe, including death. To date, it is unclear why some patients develop severe symptoms. Many authors have suggested the involvement of vitamin D in reducing the risk of infections; thus, we retrospectively investigated the 25-hydroxyvitamin D (25(OH)D) concentrations in plasma obtained from a cohort of patients from Switzerland. In this cohort, significantly lower 25(OH)D levels (p = 0.004) were found in PCR-positive for SARS-CoV-2 (median value 11.1 ng/mL) patients compared with negative patients (24.6 ng/mL); this was also confirmed by stratifying patients according to age >70 years. On the basis of this preliminary observation, vitamin D supplementation might be a useful measure to reduce the risk of infection. Randomized controlled trials and large population studies should be conducted to evaluate these recommendations and to confirm our preliminary observation.
12
5
1359
1365
Concentrations; Coronavirus; COVID-19; Deficiency; SARS-CoV-2; Vitamin D; Age Factors; Aged; Aged, 80 and over; Betacoronavirus; Coronavirus Infections; Dietary Supplements; Female; Humans; Male; Middle Aged; Pandemics; Pneumonia, Viral; Polymerase Chain Reaction; Retrospective Studies; Switzerland; Vitamin D
D'avolio A.; Avataneo V.; Manca A.; Cusato J.; De Nicolo A.; Lucchini R.; Keller F.; Cantu M.
File in questo prodotto:
File Dimensione Formato  
nutrients-12-01359-v2.pdf

Accesso aperto

Tipo di file: PDF EDITORIALE
Dimensione 1.12 MB
Formato Adobe PDF
1.12 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2318/1738840
Citazioni
  • ???jsp.display-item.citation.pmc??? 189
  • Scopus 259
  • ???jsp.display-item.citation.isi??? 237
social impact